Trusted News Discovery Since 2008
{{/content}}
Novavax COVID-19 Vaccine Becomes 5th to Reach Phase 3 Trial in the US
Video Credit: Wibbitz Top Stories
Published on December 30, 2020 - Duration: 00:49s
Novavax COVID-19 Vaccine Becomes 5th to Reach Phase 3 Trial in the US
Novavax COVID-19 Vaccine Becomes 5th to Reach Phase 3 Trial in the US.
On Monday, Novavax announced the beginning of its Phase 3 trial for its vaccine candidate, named NVX-CoV2373, in the U.S. and Mexico.
This trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world's population, Novavax President and CEO Stanley C.
Erck, via news release.
The trial will evaluate safety, efficacy and immune response in up to 30,000 people aged 18 and over.
The company also aims for at least 25% of participants to be age 65 or older and at least 15% to be Black.
Johnson & Johnson expects results from its Phase 3 trial of a single-dose vaccine by January or February
You are here
Related news from verified sources
The Phase-III clinical trial of Covid-19 vaccine (Covaxin) being developed by Bharat Biotech would begin at the privately-run Vydehi multi-specialty hospital...
on December 1, 2020 • Mid-Day
Director of the All Indian Institute of Medical Sciences (AIIMS) Dr Randeep Guleria has said that he is hopeful of that by the end of this month or early next...
on December 3, 2020 • Mid-Day
The findings of phase 1 clinical trial of the COVID-19 vaccine have appeared on medRxiv, a preprint server.
on December 16, 2020 • Hindu
Related videos from verified sources
Novavax opens Phase 3 trial for COVID-19 vaccine candidate 01:49
Video credit: ABC Action News - Published on December 29, 2020
Novavax COVID-19 Vaccine Phase 3 Trial To Begin In U.S. 00:45
Video credit: WJZ Baltimore - Published on December 28, 2020
Lenexa-based clinical research company participates in Moderna COVID-19 vaccine trial 01:31
Video credit: 41 Action News - Published on December 19, 2020